ASCOT-LLA Study: Atorvastatin vs placebo in primary prevention of CHD
- Ms. Roma Joglekar
- Sep 9
- 2 min read
Updated: Sep 10
Sever PS et al, conducted the ASCOT-LLA study to assess the efficacy of Atorvastatin 10 mg in the prevention of coronary and stroke events in hypertensive patients who have average and lower-than-average cholesterol levels.
Summary of ASCOT-LLA Study
About the Author
Ms. Roma Joglekar is a Sports Physiotherapist with three years of on-field experience in helping athletes recover, improve and excel in their performance. Roma is passionate about medical science and has keen interest in simplifying complex medical information and share it with healthcare professionals, patients, care givers and the general population.
Abbreviations
ASCOT-LLA: The Anglo-Scandinavian Cardiac Outcome Trial - Lipid Lowering Arm; CHD: Coronary Heart Disease; TC: Total Cholesterol; LDL-C: Low Density Lipoprotein Cholesterol; MI: Myocardial Infarction; CV: Cardiovascular;
Reference
Sever PS, Dahlöf B, Poulter NR, et al, for the ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT–LLA): a multicenter, randomised controlled trial. Lancet. 2003;361:1149-1158.
Disclaimer
The matter published on this platform has been developed by independent medical writers from various healthcare backgrounds including members of MedWriters Alumni Network. Although great care has been taken in compiling and checking the information, the authors, Rxnews team and its partners or agents, and sponsors shall not be responsible or in any way liable for any errors, omissions, or inaccuracies in this blog article whether arising from negligence or otherwise, however or for any consequences arising therefrom. The inclusion and exclusion of any product do not mention that the publisher advocates or rejects its use generally or in any particular field or field. For any complaints or feedback please write to content@rxnews.in
Comments